GlassScriptPhysician profile
Susan A Schulze
NPI 1568454957
$2,807.64
in general payments reported to CMS, 2019-2025
25 companies · $259 in 2025
The $259 reported for 2025 was more than what 81% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $464 · 2020: $333 · 2021: $403 · 2022: $443 · 2023: $691 · 2024: $214 · 2025: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,164.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $291.10 | 2021-2023 | Bexsero |
| Pfizer INC. | $286.28 | 2019-2024 | |
| Ironshore Pharmaceuticals INC. | $280.82 | 2019-2024 | Jornay Pm |
| Merck Sharp & Dohme LLC | $243.08 | 2019-2024 | Vaxneuvance, Gardasil 9, Vaxelis |
| Alexion Pharmaceuticals, INC. | $208.62 | 2019-2021 | |
| Biomerieux INC | $205.58 | 2023-2025 | Filmarray Torch Module |
| Ipsen Biopharmaceuticals, INC | $155.42 | 2024-2025 | Bylvay, Onivyde |
| Genzyme Corporation | $124.29 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $121.84 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $105.38 | 2019 | |
| Pharming Healthcare, INC. | $102.60 | 2023 | Joenja |
| Novartis Pharmaceuticals Corporation | $89.78 | 2020 | |
| Phadia US INC. | $87.18 | 2022-2023 | Immunocap |
| Mirum Pharmaceuticals, INC. | $85.86 | 2023 | Livmarli |
| Sanofi Pasteur INC. | $73.51 | 2023-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $72.89 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $71.68 | 2019-2020 | |
| Sobi, INC | $44.03 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $36.86 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $36.16 | 2020-2021 | |
| Vertical Pharmaceuticals, LLC | $28.70 | 2025 | Relexxii |
| Tris Pharma INC | $16.20 | 2023 | Dyanavel Xr |
| Adlon Therapeutics L.P. | $14.18 | 2020 | |
| Shire North American Group INC | $13.24 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $12.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Schulze listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.